The Effect of Atorvastatin on ADMA Level and Erectile Function in patients with Vasculogenic Erectile Dysfunction

Abstract

Abstract Background Erectile dysfunction (ED), the inability to achieve and/or maintain an erection sufficient to permit satisfactory intercourse, is a highly prevalent disease whose aetiology is mostly vasculogenic. It is associated with subclinical coronary artery disease (CAD) and is nowadays considered a marker of future cardiovascular events. The higher prevalence of ED in patients with cardiovascular risk factors(CVRF) reflects the underlying endothelial dysfunction. ADMA is a naturally occurring amino acid that exists as a result of proteolysis of methylated proteins. Several factors, such as oxidative stress and increased levels of low-density lipoproteins (LDLs), are responsible for induced production of ADMA in endothelial cells. In our study, atorvastatin administration resulted in a significant decrease in ADMA levels and improvement of erectile function Aim To demonstratethe effect of Atorvastatin on ADMA level and erectile function in patients with normal or high LDL level vasculogenic erectile dysfunction. Patients and Methods The study will include 30 patients aged 30-60 years old with vasculogenic erectile dysfunction.The patients will be collected from The Andrology Outpatient Clinic – Ain-Shams University Hospitals. Results Among the study group 10 subjects showed moderate elevation of plasma ADMA (33.3%), 10 subjects with high level (33.3%) and 10 subjects with normal level (33.3%), while in control group only 5 subjects had high ADMA level, one subjects with moderate elevation and 24 subjects had normal level (80%) There was high significant reduction in both ADMA and LDL level after atorvastatin treatment and significant improvement in IIEF score, However no significant change in Testosterone level CONCLUSIONS We demonstrated that short-term treatment with atorvastatin has great influence on plasma ADMA levels with marked improvement in lipid profile (LDL) and erectile function in both normolipidemic and dyslipidenic patients.